Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1060

1.

Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.

Hsu HY, Lin TY, Hwang PA, Tseng LM, Chen RH, Tsao SM, Hsu J.

Carcinogenesis. 2013 Apr;34(4):874-84. doi: 10.1093/carcin/bgs396. Epub 2012 Dec 28.

2.
4.

Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.

Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D, Mukai J, Sakaguchi K, Satou T, Nishida S.

J Exp Clin Cancer Res. 2013 Sep 5;32:62. doi: 10.1186/1756-9966-32-62.

5.

An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.

Park CY, Min KN, Son JY, Park SY, Nam JS, Kim DK, Sheen YY.

Cancer Lett. 2014 Aug 28;351(1):72-80. doi: 10.1016/j.canlet.2014.05.006. Epub 2014 Jun 2.

PMID:
24887560
6.

ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.

Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, Bondesson M, Quinlan P, Thompson A, Krishnamurthy S, Esteva FJ, Gustafsson JÅ.

Breast Cancer Res. 2012 Nov 16;14(6):R148. doi: 10.1186/bcr3358.

7.

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J.

Br J Cancer. 2014 Mar 18;110(6):1497-505. doi: 10.1038/bjc.2014.80. Epub 2014 Feb 25.

8.

Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer.

Guo BH, Feng Y, Zhang R, Xu LH, Li MZ, Kung HF, Song LB, Zeng MS.

Mol Cancer. 2011 Jan 28;10(1):10. doi: 10.1186/1476-4598-10-10.

9.

Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype.

Li NY, Weber CE, Mi Z, Wai PY, Cuevas BD, Kuo PC.

J Am Coll Surg. 2013 Jul;217(1):17-26; discussion 26. doi: 10.1016/j.jamcollsurg.2013.02.025. Epub 2013 Apr 23. Erratum in: J Am Coll Surg. 2015 Aug;221(2):642.

PMID:
23619316
10.

Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.

Fang Y, Chen Y, Yu L, Zheng C, Qi Y, Li Z, Yang Z, Zhang Y, Shi T, Luo J, Liu M.

J Natl Cancer Inst. 2013 Jan 2;105(1):47-58. doi: 10.1093/jnci/djs485. Epub 2012 Nov 24.

11.

Moscatilin inhibits migration and metastasis of human breast cancer MDA-MB-231 cells through inhibition of Akt and Twist signaling pathway.

Pai HC, Chang LH, Peng CY, Chang YL, Chen CC, Shen CC, Teng CM, Pan SL.

J Mol Med (Berl). 2013 Mar;91(3):347-56. doi: 10.1007/s00109-012-0945-5. Epub 2012 Sep 8.

PMID:
22961111
12.

Transforming growth factor-β 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition.

Lv ZD, Kong B, Li JG, Qu HL, Wang XG, Cao WH, Liu XY, Wang Y, Yang ZC, Xu HM, Wang HB.

Oncol Rep. 2013 Jan;29(1):219-25. doi: 10.3892/or.2012.2111. Epub 2012 Oct 30.

PMID:
23129177
13.

miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer.

Yu J, Xie F, Bao X, Chen W, Xu Q.

Mol Cancer. 2014 May 24;13:121. doi: 10.1186/1476-4598-13-121.

14.

EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.

Park CY, Son JY, Jin CH, Nam JS, Kim DK, Sheen YY.

Eur J Cancer. 2011 Nov;47(17):2642-53. doi: 10.1016/j.ejca.2011.07.007. Epub 2011 Aug 16.

PMID:
21852112
15.

Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition.

Liu Z, Zhang B, Liu K, Ding Z, Hu X.

PLoS One. 2012;7(7):e40480. doi: 10.1371/journal.pone.0040480. Epub 2012 Jul 25.

16.

IKK(α) controls canonical TGF(ß)-SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in panc1 cells.

Brandl M, Seidler B, Haller F, Adamski J, Schmid RM, Saur D, Schneider G.

J Cell Sci. 2010 Dec 15;123(Pt 24):4231-9. doi: 10.1242/jcs.071100. Epub 2010 Nov 16. Erratum in: J Cell Sci. 2013 Jun 15;126(Pt 12):2747.

17.

Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling.

Khan S, Shukla S, Sinha S, Lakra AD, Bora HK, Meeran SM.

Int J Biochem Cell Biol. 2015 Jan;58:1-16. doi: 10.1016/j.biocel.2014.10.028. Epub 2014 Nov 7.

PMID:
25448414
18.

Specific interactions between Smad proteins and AP-1 components determine TGFβ-induced breast cancer cell invasion.

Sundqvist A, Zieba A, Vasilaki E, Herrera Hidalgo C, Söderberg O, Koinuma D, Miyazono K, Heldin CH, Landegren U, Ten Dijke P, van Dam H.

Oncogene. 2013 Aug 1;32(31):3606-15. doi: 10.1038/onc.2012.370. Epub 2012 Aug 27.

PMID:
22926518
19.

3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.

Tsai JH, Hsu LS, Lin CL, Hong HM, Pan MH, Way TD, Chen WJ.

Toxicol Appl Pharmacol. 2013 Nov 1;272(3):746-56. doi: 10.1016/j.taap.2013.07.019. Epub 2013 Aug 3.

PMID:
23921149
20.

Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics.

Dang H, Ding W, Emerson D, Rountree CB.

BMC Cancer. 2011 Sep 19;11:396. doi: 10.1186/1471-2407-11-396.

Items per page

Supplemental Content

Write to the Help Desk